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Many of the standard cell culturing unit operations utilized by early stage CAR-T manufacturing processes have 
been derived from benchtop scale academic processes and require further development to become 
commercially viable. Critical unit operations, such as isolation, activation, transduction, and expansion are often 
the focus of next generation or automation technologies. Development of ancillary processes such as medium 
production, however, should not be overlooked and can take advantage of economies of scale and technologies 
that have been proven in other pharmaceutical industries like biologics. Special consideration should be taken 
when developing these medium scale-up processes since cell therapies are complex and can be highly 
sensitive to medium composition changes. In addition, significant changes may be needed to update medium 
production processes from a process suited for an academic setting to one suited for a commercialized product. 
This poster discusses Celgene’s approach for developing a commercially sustainable media preparation 
process by applying available filtration and bulk solution preparation technologies and the unique challenges 
associated with applying these technologies to CAR-T therapies.  
 
 
 
